Key result
Four-week smartphone HRV biofeedback modestly increases low-frequency HRV versus controls.
Why the study?
Breast cancer survivors experience chronic symptoms linked to autonomic dysfunction, but effective non-pharmacological solutions to address them are lacking.
Does a 4-week remote smartphone-based heart rate variability biofeedback intervention improve heart rate variability and self-reported cancer-related symptoms in women with a history of primary breast cancer?
RCT (n=60)
three-armed
Does a 4-week remote smartphone-based heart rate variability biofeedback intervention improve heart rate variability and self-reported cancer-related symptoms in women with a history of primary breast cancer?
Standardized Mean Difference: 0.33
p-value: p=0.027
A 4-week smartphone-based heart rate variability biofeedback intervention significantly improves autonomic function and chronic symptoms such as poor sleep quality and anxiety in breast cancer survivors.
Remote HRV biofeedback improves autonomic function in breast cancer survivors; extends RCT evidence for scalable digital interventions.
Breast cancer survivors experience numerous chronic symptoms linked to autonomic dysfunction including anxiety, stress, insomnia, menopausal symptoms, and cognitive impairment. Effective non-pharmacological solutions to address these are currently lacking. Methods: Our three-armed longitudinal randomized controlled trial assessed the effectiveness of a 4-week remote smartphone-based heart rate variability biofeedback intervention which involved daily paced breathing at 6 breaths p/min; active (12 breaths p/min) and waitlist controls were included. Heart rate variability and self-reported cancer-related symptoms were assessed at baseline, post-, and 6 months-post intervention. Participants were 60 UK-based women with primary breast cancer history (6 to 60 months post-active treatment). Results: The intervention group showed significant increases in low-frequency heart rate variability over time (F (4, 103.89) = 2.862, p = 0.027, d = 0.33), long-lasting improvement in sleep quality (F (4, 88.04) = 4.87, p = 0.001, d = 0.43) and cessations in night sweats (X2 (2, N = 59) = 6.44, p = 0.04, Cramer’s V = 0.33), and reduced anxiety post-intervention compared to the active and waitlist controls (F (4, 82.51) = 2.99, p = 0.023, d = 0.44). Other findings indicated that the intervention and active control participants reported lasting improvements in cognitive function, fatigue, and stress-related symptoms (all ps < 0.05). The waitlist group reported no symptom changes across time. Conclusion: Heart rate variability biofeedback is a feasible intervention for addressing diverse chronic symptoms commonly reported by breast cancer survivors.
No takes yet. Share an insight, caveat, or question.
Dolgilevica et al. (2025) conducted an RCT in Primary breast cancer (n=60). Smartphone-based heart rate variability biofeedback vs. active (12 breaths p/min) and waitlist controls was evaluated on low-frequency heart rate variability (d = 0.33, p=0.027). A 4-week smartphone-based heart rate variability biofeedback intervention significantly increased low-frequency heart rate variability (p=0.027, d=0.33) compared to active and waitlist controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: